Only one drug for patients with systemic lupus erythematosus (SLE), belimumab, has been approved on the basis of support from a randomized, placebo-controlled trial, and numerous development programs of immunomodulatory treatments have failed to show benefits with respect to primary end points in phase 3 trials. Patients continue to be burdened with complications from uncontrolled disease and from adverse effects and risks associated with glucocorticoids and immunosuppressive drugs that are used to treat lupus. Morand et al. now report in the Journal a successful phase 3 trial, TULIP-2 (Treatment of Uncontrolled Lupus via the Interferon Pathway–2),1 in which the active . . .